Why the study?
Does apixaban 2.5 mg BID provide more constant anticoagulation compared with rivaroxaban 10 mg QD?
Does apixaban 2.5 mg BID provide more constant anticoagulation compared with rivaroxaban 10 mg QD?
Apixaban 2.5 mg BID provides more constant anticoagulation with smaller peak-to-trough fluctuations compared to rivaroxaban 10 mg QD, though the clinical implications remain unknown.
Apixaban 2.5 mg BID may yield more constant anticoagulation than rivaroxaban 10 mg QD; leaves open whether fluctuations affect clinical outcomes.
Apixaban 2.5 mg BID demonstrated less intersubject variability in exposure, lower AXA AUC, and higher trough and smaller peak-to-trough fluctuations in plasma concentration and AXA, suggesting more constant anticoagulation compared with rivaroxaban 10 mg QD. However, the clinical impact of these differences on the relative efficacy and safety of apixaban and rivaroxaban remains to be determined.
No takes yet. Share an insight, caveat, or question.
Frost et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: